CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CRMD
Previous SymbolNYSEMKT:CRMD
CUSIPN/A
Phone+1-908-5179500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees14
Outstanding Shares105,310,000
Market Cap$0.00
OptionableOptionable
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) issued its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.10 million. View CorMedix's Earnings History.
When is CorMedix's next earnings date?
What price target have analysts set for CRMD?
2 equities research analysts have issued 12-month price objectives for CorMedix's stock. Their forecasts range from $3.50 to $6.00. On average, they anticipate CorMedix's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 239.3% from the stock's current price. View Analyst Price Targets for CorMedix.
What is the consensus analysts' recommendation for CorMedix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.
What are Wall Street analysts saying about CorMedix stock?
Here are some recent quotes from research analysts about CorMedix stock:
- 1. According to Zacks Investment Research, "CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey. " (12/14/2018)
- 2. HC Wainwright analysts commented, "We derive a value of $470M for Neutrolin using a 12% discount rate and 90% probability of success, along with a 23% effective tax rate, or a price per share of $3.50, taking into account $150M from additional value drivers (ex-U.S." (12/12/2018)
Has CorMedix been receiving favorable news coverage?
Headlines about CRMD stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CorMedix earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Are investors shorting CorMedix?
CorMedix saw a increase in short interest in November. As of November 30th, there was short interest totalling 13,318,889 shares, an increase of 7.8% from the November 15th total of 12,351,937 shares. Based on an average daily volume of 2,536,101 shares, the days-to-cover ratio is currently 5.3 days. Currently, 13.3% of the company's shares are sold short. View CorMedix's Current Options Chain.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 60)
- Mr. Robert W. Cook, Chief Financial Officer (Age 62)
- Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)
- Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance
Who are CorMedix's major shareholders?
CorMedix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (2.54%), Vanguard Group Inc. (2.54%), EAM Investors LLC (0.72%), Virtu Financial LLC (0.39%) and Franklin Resources Inc. (0.17%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.
Which institutional investors are selling CorMedix stock?
Which institutional investors are buying CorMedix stock?
CRMD stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., EAM Investors LLC and Virtu Financial LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.
How do I buy shares of CorMedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $1.40.
What is CorMedix's official website?
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
